Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 13/20 | 0.52 |
| ▸ | KDM1A | O60341 | 3/20 | 0.43 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | AGXT | P21549 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8220219 | 0.82 | SLC13A5 (0.48) | IDO1KDM1ASLC13A5MAOAMAOB | |
| SCHEMBL29587038 | 0.81 | KDM1A (0.46) | KDM1ASLC13A5MAOAMAOBAPLNR | |
| SCHEMBL1265988 | 0.81 | KDM1A (0.46) | KDM1ASLC13A5MAOAMAOBAPLNR | |
| Hydrochloric Acid SCHEMBL5900832 | 0.79 | KDM1A (0.44) | KDM1ASLC13A5MAOAMAOBAPLNR | |
| Hydrochloric Acid SCHEMBL16797857 | 0.79 | KDM1A (0.44) | KDM1ASLC13A5MAOAMAOBAPLNR | |
| SCHEMBL91503 | 0.79 | SLC13A5 (0.50) | KDM1ASLC13A5MAOAMAOBAPLNR | |
| SCHEMBL28960253 | 0.78 | SLC13A5 (0.48) | KDM1ASLC13A5MAOAMAOB | |
| SCHEMBL3055288 | 0.78 | TAAR1 (0.52) | KDM1ASLC13A5MAOAMAOBAPLNR | |
| SCHEMBL13359015 | 0.77 | HPGD (0.44) | KDM1ASLC13A5MAOAMAOBAPLNR | |
| SCHEMBL6588356 | 0.77 | SLC13A5 (0.49) | KDM1ASLC13A5MAOAMAOBAPLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| EP-2040698-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008008398-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | IDO1 305/4885KDM1A 1271/4885SLC13A5 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.